A study on the utility of inflammatory biomarkers in primary care irritable bowel syndrome: a sub analysis of the DOMINO randomized trial.

ABSTRACT:

Background

The role of low-grade-inflammation in Irritable Bowel Syndrome (IBS) a common disorder of gut-brain interaction is unclear. Association with symptom severity, as well as effects of first line treatments are understudied. In a large cohort of primary care IBS patients (DOMINO trial), a FODMAP-lowering diet application was superior in improving symptoms compared to standard medical therapy (otilonium bromide, OB). We investigated the level of pro-inflammatory markers in this IBS cohort and its changes by the DOMINO application and OB.

Methods

Inflammatory markers fecal calprotectin (FC), secretory IgA (sIgA), beta-defensin 2 (HBD-2), fecal elastase (Fel-1), and C-reactive protein (CRP) were analyzed at baseline and after 8-week of treatment (diet or medication). In

SUBMITTER: Tack C 

PROVIDER: S-EPMC12836962 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature